Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that they have entered into a license agreement for two ...

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Nvidia Corp. Chief Executive Jensen Huang didn’t exactly please Wall Street at the so-called Super Bowl of AI. But now he’s giving President Donald Trump credit for his company’s new ...

New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board ...

Flywl Receives Top Startup Award At SIG Conference. Awarded by a panel of industry leaders from Zillow, Sanofi, Lucid Motors, and more ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal focuses on developing neurodegenerative disease treatments.

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

New CEO Lip-Bu Tan aims to streamline the workforce and focus on AI chip production, hoping to revitalize Intel's competitive edge. Under his leadership, Intel's revenue plummeted to $54 billion ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...